131 results
8-K
EX-10.1
w9niw6r8m3cqpum ba
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
5d3z20zzsxy10b
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-10.2
5bah9oer
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.1
a9yrdh6 naeai7lhogd
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.3
bghy3jeb8i ra5zhr
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.1
ybogh9b7yh52 hjg
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
y62fl
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
02clzfwn e06n0
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
7qkzn8hhd6r98gsoqpj
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
x3huv0
30 May 23
Business combination disclosure
4:21pm
8-K
bp7nkfv2qh r8
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
mq4ro8n2be 3wu
22 May 23
Business combination disclosure
7:01am
8-K
vxix2xpzso7
22 May 23
Other Events
6:59am